| Identification | Back Directory | [Name]
Latamoxef sodium | [CAS]
64953-12-4 | [Synonyms]
6059s
moxam
S 6059
ly127935
LY 12735
HY-B1484
Shiomarin
Festamoxin
FestamoxinLy
Shionogi 6059S
latamoxefsodium
antibiotic6059-s
Einecs 265-288-4
Latamoxef sodiumr
disodiumlatamoxef
moxalactam sodium
moxalactamdisodium
Latamoxef Disodium
MOXALACTAM SODIUM SALT
Latamoxef sodium USP/EP/BP
Moxalactam Disodium (500 mg)
Moxalactam sodium, >=830 μg/mg
moxalactam sodium salt, mixture of isomers
MoxalactaM SodiuM Salt (Mixture of diastereoMers)
Moxalactam Sodium Salt (Mixture of Diastereomers) (10mM in DMSO)
5-oxa-1-azabicyclo(4.2.o)oct-2-ene-2-carboxylicacid,7-((carboxy(4-hydroxyphen
disodium 7-[[carboxylato(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
5-Oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-, disodium salt
(6R,7R)-7-[2-Carboxy-2-(p-hydroxyphenyl)acetylamino]-7-methoxy-3-(1-methyl-1H-tetrazol-5-ylthiomethyl)-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid disodium salt
(6R,7R)-7-[[(2R)-Carboxy(4-hydroxyphenyl)acetyl]aMino]-7-Methoxy-3-[[(1-Methyl-1H-tetrazol-5-yl)thio]Methyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid DisodiuM Salt
5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2R)-2-carboxy-2-(4-hydroxyphenyl)acetyl]aMino]-7-Methoxy-3-[[(1-Methyl-1H-tetrazol-5-yl)thio]Methyl]-8-oxo-,sodiuM salt (1:2), (6R,7R)-
5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, disodium salt, (6R,7R)- (9CI) | [EINECS(EC#)]
265-288-4 | [Molecular Formula]
C20H18N6Na2O9S | [MDL Number]
MFCD03427565 | [MOL File]
64953-12-4.mol | [Molecular Weight]
564.44 |
| Chemical Properties | Back Directory | [Melting point ]
>156oC (dec.) | [alpha ]
D22 -45° (water) | [storage temp. ]
2-8°C
| [solubility ]
Methanol (Slightly) | [form ]
White to Pale Yellow | [Merck ]
13,6311 | [Stability:]
Unstable in solution (DMSO or Methanol) | [InChIKey]
GRIXGZQULWMCLU-GDUWRUPCSA-L |
| Hazard Information | Back Directory | [Originator]
Moxam,Lilly,US,1981 | [Uses]
Antibacterial;Bacterial transpeptidase inhibitor | [Uses]
Moxalactam Sodium is an oxacephem antibiotic. Moxalactam Sodium is more effective against Escherichia coli and Pseudomonas aeruginosa than cephalosporins. | [Manufacturing Process]
To a stirred suspension of p-(p-methoxybenzyloxy)-phenylmalonic acid (125
mg) in methylene chloride (3 ml) are added triethylamine (55 l) and oxalyl
chloride (26 l) at -15°C, and the suspension is stirred for 40 minutes at 0°C.
The mixture is added to a solution of diphenylmethyl 7β-amino-7α-methoxy-3-
(1-methyltetrazol-5-yl)thiomethyl-1-oxadethia-3-cephem-4-carboxylate (100
mg) in methylene chloride (3 ml) and pyridine (63 l), and the mixture is
stirred for 30 minutes at 0°C. The reaction mixture is diluted with ethyl
acetate, washed with aqueous 2N-hydrochloric acid and water, dried over
sodium sulfate, and concentrated to give crude product (212 mg), which is
chromatographed on silica gel (20 g) and eluted with a mixture of ethyl
acetate and acetic acid (99:1) to give diphenylmethyl-7β-[α-p-(pmethoxybenzyloxy)phenyl-α-carboxyacetamido]-7α-methoxy-3-(1-
methyltetrazol-5yl)thiomethyl-1-oxadethia-3-cephem-4-carboxylate as foam
(71 mg). Yield: 45%.
To a solution of diphenylmethyl-7β-[α-p-(p-methoxybenzyl)-oxy-phenyl-α-pmethoxybenzyl-oxycarbonil-acetamido]-7α-methoxy-3-(1-methyltetrazol-5-
yl)thiomethyl-1-oxadethia-3-cephem-4-carboxylate (1.20 g) in methylene
chloride (24 ml) are added anisole (2.4 ml) and a solution of aluminum
chloride (2.58 g) in nitromethane (12 ml) at 0°C under nitrogen. After stirring
for 15 minutes at 0°C, the mixture is poured into cold 5% sodium hydrogen
carbonate aqueous solution (100 ml) and filtered to remove the formed
precipitate. The filtate is washed twice with methylene chloride (2 x 100 ml),
acidified with 2N-hydrochloric acid to pH 2.60, and poured in a column of high
porous polymer HP-20 (60 ml) sold by Mitsubishi Chemical Industries Ltd. The
column is washed with water (300 ml) and eluted with methanol. The eluate
is concentrated under reduced pressure at room temperature. The residue is
dissolved in methanol, treated with active carbon, and concentrated under
reduced pressure to give 7β(α-p-hydroxyphenyl-α-carboxyacetamido)-7β-
methoxy-3-(1-methyl-tetrazol-5-yl)thiomethyl1-oxadethia-3-cephem-4-
carboxylic acid as powder (595 mg) decomposing at 125°C to 132°C. Yield:
88.5%.
To a solution of 7β(α-p-hydroxyphenyl-α-carboxyacetamido)-7α-methoxy-3-(1-
methyl-tetrazol-5-yl)thiomethyl1-oxadethia-3-cephem-4-carboxylic acid (359
mg) in methanol (7 ml) is added a solution of sodium 2-ethylhexanoate in
methanol (2 mols/liter; 1.73 ml) at room temperature. After stirring for 10
minutes, the reaction mixture is diluted with ethyl acetate, stirred for 5
minutes, and filtered to collect separated solid, which is washed with ethyl
acetate, and dried to give disodium salt of 7β(α-p-hydroxyphenyl-α-
carboxyacetamido)-7α-methoxy-3-(1-methyl-tetrazol-5-yl)thiomethyl1-
oxadethia-3-cephem-4-carboxylic acid (342 mg). Yield: 888%. Colorless
powder. MP decomposition from 170°C. | [Brand name]
Moxam (Lilly). | [Therapeutic Function]
Antiinfective | [Biological Activity]
moxalactam (sodium salt) is a β-lactam antibiotic.β-lactam antibiotics (beta-lactam antibiotics) are a class of broad-spectrum antibiotics that contain a beta-lactam ring in their molecular structures. most β-lactam antibiotics act by inhibiting cell wall biosynthesis.moxalactam is an oxacephem antibiotic and inhibits most commonly occurring gram positive, gram negative, and anaerobic bacteria. moxalactam was more active against klebsiella and e coli than cefoperazone. moxalactam did not inhibit methicillin-resistant s. aureus and enterococci. moxalactam had been extremely active against haemophilis and neisseria gonorrhoeae. moxalactam was extremely resistant to hydrolysis by all plasmid and chromosmal β-lactamases [1]. in certain situations, moxalactam impaired normal hemostasis and prolonged bleeding time [2]. | [References]
[1]. neu hc. the in vitro activity, human pharmacology, and clinical effectiveness of new beta-lactam antibiotics. annu rev pharmacol toxicol. 1982;22:599-642.
[2]. sattler fr, weitekamp mr, ballard jo. potential for bleeding with the new beta-lactam antibiotics. ann intern med. 1986 dec;105(6):924-31. |
|
|